Samsung Bioepis to Seek Pause of Order Blocking Eylea Biosimilar

Samsung Bioepis Co. wants to pause the preliminary injunction a West Virginia federal court issued last week blocking its biosimilar of Regeneron Pharmaceuticals Inc.’s blockbuster Eylea while Samsung’s appeal plays out, according to court filings.

The Samsung Biologics Co. unit revealed its intention in a motion for permission to file the emergency bid under seal, filed Wednesday in the US District Court for the Northern District of West Virginia. Chief Judge Thomas S. Kleeh granted the request Thursday afternoon.

• Kleeh on June 14 granted Regeneron’s request for an order blocking Samsung’s biosimilar of the age-related macular-degeneration treatment, called SB15 or ...